COMMUNIQUÉS West-GlobeNewswire

Agios Presents Updated Data from DRIVE PK Study Demonstrating AG-348 is Well-Tolerated and Results in Clinically Relevant, Rapid and Sustained Hemoglobin Increases in Patients with Pyruvate Kinase Deficiency

11/12/2017 - 00:00

– Safety and Efficacy Profile Consistent with Previously Reported Data – – Hemoglobin Increases >1.0 g/dL in 26 of 52 Patients Overall; Responses Remain Durable with Completion of Six Month Core Treatment Period – – [...]

ZIOPHARM Announces Presentation of Data from T-Cell Therapy Programs at ASH Annual Meeting

10/12/2017 - 23:00

– Clinical data show continued survival benefit, tumor response, and multi-year persistence of Sleeping Beauty -modified CD19-specific CAR + T cells – – Point-of-care CD19-specific CAR + T cells co-expressing mbIL15 [...]

Primary analysis results from Novartis pivotal JULIET trial show Kymriah(TM) (tisagenlecleucel) sustained complete responses at six months in adults with r/r DLBCL, a difficult-to-treat cancer

10/12/2017 - 16:39

At six months, 30% of patients treated with Kymriah were in complete response, with a 74% relapse-free rate after onset of response; median duration of response was not reached Grade 3/4 neurologic events occurred in 12 [...]

Epizyme Presents New Biomarker Data on Tazemetostat at the American Society of Hematology Annual Meeting

10/12/2017 - 16:00

CAMBRIDGE, Mass., Dec. 10, 2017 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ: EPZM ), a clinical-stage biopharmaceutical company developing novel epigenetic therapies, today announced that two presentations reinforcing its [...]

Combination of G100 with KEYTRUDA (pembrolizumab) Triggers Robust Systemic Responses in Follicular NHL Patients

10/12/2017 - 15:00

39% ORR for G100+pembrolizumab is greater than either agent alone; reaches 57% ORR in the TLR4 high patient population receiving G100+pembrolizumab (potential predictive biomarker) Responses occur in both recurrent/ [...]

Kura Oncology Reports Positive Phase 2 Study of Tipifarnib in Chronic Myelomonocytic Leukemia

10/12/2017 - 15:00

– Primary objective met with three objective responses in nine patients with RAS wild-type tumor status (33%), two additional RAS wild-type patients pending best response evaluation – – All nine evaluable patients with [...]

On Cancellation of the Webinar Scheduled for December 12

10/12/2017 - 13:45

Olaine, 2017-12-10 13:45 CET (GLOBE NEWSWIRE) -- AS Olainfarm hereby informs, that 3rd quarter webinar scheduled for 4:00 p.m. Latvian time on December 12, 2017 is cancelled. Company will publish a separate announcement [...]

CRISPR Therapeutics Announces Oral Presentation of New Data on CTX001, a CRISPR Gene-Edited Therapy for β-Thalassemia and Sickle Cell Disease, at the ASH Annual Meeting

10/12/2017 - 13:45

ZUG, Switzerland and CAMBRIDGE, Mass., Dec. 10, 2017 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ: CRSP ) today announced the presentation of new data on CTX001, an investigational CRISPR gene-edited therapy for [...]

Valerijs Maligins, Chairman of the Board of AS Olainfarm Has Passed Away

10/12/2017 - 13:33

Olaine, 2017-12-10 13:33 CET (GLOBE NEWSWIRE) -- Valerijs Maligins became Chairman of Olainfarm’s Board after the privatization of the company in 1997. Under his management, the company became one of the most valuable [...]

Bellicum Announces Data Presentation Demonstrating Improved Immune Recovery Following Haploidentical Stem Cell Transplant with BPX-501 in Children with Blood Cancers and Nonmalignant Diseases

09/12/2017 - 20:00

ATLANTA, Dec. 09, 2017 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ: BLCM ), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today [...]

BeiGene Presents Preliminary Phase 1b Data on BTK Inhibitor Zanubrutinib (BGB-3111) in Non-Hodgkin’s Lymphoma at the 59th American Society of Hematology Annual Meeting

09/12/2017 - 18:15

CAMBRIDGE, Mass. and BEIJING, China, Dec. 09, 2017 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE ), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly [...]

GBT Announces New Phase 2a Data at ASH for Voxelotor in Adolescents with Sickle Cell Disease (SCD)

09/12/2017 - 16:00

SOUTH SAN FRANCISCO, Calif., Dec. 09, 2017 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT ) today announced new results from its ongoing Phase 2a HOPE-KIDS 1 Study of once-daily oral therapy, [...]

Catalyst Biosciences Announces Interim Phase 1/2 CB 2679d/ISU304 Results at the American Society of Hematology Conference

09/12/2017 - 15:30

Subcutaneous (SQ) delivery significantly increases half-life of CB 2679d to 98.7 hours Data supports potential normalization of FIX activity with daily or less-frequent SQ dosing SOUTH SAN FRANCISCO, Calif., Dec. 09, [...]

BeiGene Presents Updated Preliminary Phase 1b Data on BTK Inhibitor Zanubrutinib (BGB-3111) Combined with GAZYVA® (Obinutuzumab) at the 59th American Society of Hematology Annual Meeting

09/12/2017 - 15:00

CAMBRIDGE, Mass. and BEIJING, China, Dec. 09, 2017 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE ), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly [...]

Rhizen Pharmaceuticals S.A. receives FDA Fast Track Designation for RP6530 (tenalisib), a highly selective dual PI3K delta/gamma inhibitor for the treatment of patients with relapsed/refractory peripheral T-cell lymphoma (PTCL)

09/12/2017 - 14:00

La Chaux-de-Fonds, Switzerland, Dec. 09, 2017 (GLOBE NEWSWIRE) -- Rhizen Pharmaceuticals S.A., today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for RP6530 (tenalisib), [...]

Myriad Genetics Presents Results From Two Important EndoPredict® Studies at the 2017 San Antonio Breast Cancer Symposium

09/12/2017 - 00:00

SALT LAKE CITY, Dec. 08, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics , Inc. (NASDAQ: MYGN ), a leader in molecular diagnostics and personalized medicine, today announced new results from two studies with EndoPredict ® are [...]

JDRF welcomes CRA review of diabetes denials

08/12/2017 - 22:46

TORONTO, Dec. 08, 2017 (GLOBE NEWSWIRE) -- The 300,000+ Canadians and their families living with type 1 diabetes (T1D) across the country welcome today’s announcement that the Government of Canada and the Canada Revenue [...]

Apellis Pharmaceuticals Presents Update on Phase 1b PHAROAH Trial of APL-2 in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) at Annual Scientific Assembly of the International PNH Interest Group (IPIG)

08/12/2017 - 22:34

LOUISVILLE, Ky. and CAMBRIDGE Mass., Dec. 08, 2017 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS ) , a clinical-stage biopharmaceutical company developing a platform of novel therapeutic compounds for [...]

Cytokinetics Announces Presentation of Results From VITALITY-ALS at 28th International Symposium on ALS/MND

08/12/2017 - 22:20

Previously Announced Results from Phase 3 Clinical Trial of Tirasemtiv Shared with ALS Community VITALITY-ALS Did Not Meet Primary or Secondary Endpoints Trial Informs Development of Next Generation Drug Candidate SOUTH [...]